Conversion of Unmodified Stem Cells to Pacemaker Cells by Overexpression of Key Developmental Genes

被引:4
|
作者
Karimi, Tahereh [1 ,2 ]
Pan, Zhizhong [3 ]
Potaman, Vladimir N. [2 ,4 ]
Alt, Eckhard U. [1 ,2 ,4 ,5 ,6 ]
机构
[1] Tulane Univ, Heart & Vasc Inst, Hlth Sci Ctr, Dept Med, 1430 Tulane Ave, New Orleans, LA 70112 USA
[2] Alliance Cardiovasc Researchers, 2211 Augusta Dr 10, Houston, TX 77057 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] InGeneron Inc, 8205 El Rio St, Houston, TX 77054 USA
[5] Univ South Dakota, Sanford Hlth, Sioux Falls, SD 57104 USA
[6] Isar Klinikum Munich, Sonnenstr 24-26, D-80331 Munich, Germany
关键词
adipose-derived stem cells; transcription factors; ion channels; pacemaker cells; CARDIAC CONDUCTION SYSTEM; STROMAL CELLS; CLINICAL-IMPLICATIONS; ADIPOSE-TISSUE; DIFFERENTIATION; HEART; CARDIOMYOCYTES; FIBROBLASTS; GENERATION; EXPRESSION;
D O I
10.3390/cells12101381
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Arrhythmias of the heart are currently treated by implanting electronic pacemakers and defibrillators. Unmodified adipose tissue-derived stem cells (ASCs) have the potential to differentiate into all three germ layers but have not yet been tested for the generation of pacemaker and Purkinje cells. We investigated if-based on overexpression of dominant conduction cell-specific genes in ASCs-biological pacemaker cells could be induced. Here we show that by overexpression of certain genes that are active during the natural development of the conduction system, the differentiation of ASCs to pacemaker and Purkinje-like cells is feasible. Our study revealed that the most effective procedure consisted of short-term upregulation of gene combinations SHOX2-TBX5-HCN2, and to a lesser extent SHOX2-TBX3-HCN2. Single-gene expression protocols were ineffective. Future clinical implantation of such pacemaker and Purkinje cells, derived from unmodified ASCs of the same patient, could open up new horizons for the treatment of arrythmias.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Conversion of Stem Cells to Cancer Stem Cells: Undercurrent of Cancer Initiation
    Afify, Said M.
    Seno, Masaharu
    CANCERS, 2019, 11 (03)
  • [22] Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells
    Meissner, Alexander
    Wernig, Marius
    Jaenisch, Rudolf
    NATURE BIOTECHNOLOGY, 2007, 25 (10) : 1177 - 1181
  • [23] Identification of key genes and pathways associated with osteogenic differentiation of adipose stem cells
    Zhao, Xinyuan
    Liang, Minlu
    Li, Xiaona
    Qiu, Xiaoling
    Cui, Li
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (12) : 9777 - 9785
  • [24] Asymmetric cell kinetics genes: The key to expansion of adult stem cells in culture
    Sherley, JL
    STEM CELLS, 2002, 20 (06) : 561 - 572
  • [25] DEVELOPMENTAL REGULATION OF GENES IN CELLS AND MICE
    TILGHMAN, SM
    IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY, 1987, 23 (03): : A12 - A12
  • [26] TBX18 transcription factor overexpression in human-induced pluripotent stem cells increases their differentiation into pacemaker-like cells
    Gorabi, Armita M.
    Hajighasemi, Saeideh
    Tafti, Hossein A.
    Atashi, Amir
    Soleimani, Masoud
    Aghdami, Nasser
    Saeid, Ali K.
    Khori, Vahid
    Panahi, Yunes
    Sahebkar, Amirhossein
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (02) : 1534 - 1546
  • [27] Pluripotent stem cells in developmental biology
    Ikeya, Makoto
    Toyooka, Yayoi
    Eiraku, Mototsugu
    DEVELOPMENT GROWTH & DIFFERENTIATION, 2021, 63 (01) : 3 - 4
  • [28] Developmental origins of hematopoietic stem cells
    Robin, C
    Ottersbach, K
    de Bruijn, M
    Ma, X
    van der Horn, K
    Dzierzak, E
    ONCOLOGY RESEARCH, 2003, 13 (6-10) : 315 - 321
  • [29] Developmental plasticity of stem cells and diseases
    Luo, Guopei
    Long, Jiang
    Zhang, Bo
    Liu, Chen
    Xu, Jin
    Yu, Xianjun
    Ni, Quanxing
    MEDICAL HYPOTHESES, 2010, 75 (06) : 507 - 510
  • [30] A developmental route to hematopoietic stem cells
    Wilkinson, Adam C.
    de Bruijn, Marella F. T. R.
    NATURE BIOTECHNOLOGY, 2024,